These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 26062742)

  • 1. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
    Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
    PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
    Yamaguchi A; Usami K; Shimabe M; Hasegawa K; Asada M; Motoki K; Tahara T; Masuda K
    Anticancer Res; 2015 Apr; 35(4):1997-2004. PubMed ID: 25862852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
    Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
    J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
    Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
    Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
    Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
    Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
    Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
    Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
    Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
    Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
    Zisman A; Pantuck AJ; Bui MH; Said JW; Caliliw RR; Rao N; Shintaku P; Berger F; Gambhir SS; Belldegrun AS
    Cancer Res; 2003 Aug; 63(16):4952-9. PubMed ID: 12941820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
    Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
    J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
    Mulders P; Bleumer I; Debruyne F; Oosterwijk E
    Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
    Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
    Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
    Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
    PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
    Schroten C; Kraaij R; Veldhoven JL; Berrevoets CA; den Bakker MA; Ma Q; Sadelain M; Bangma CH; Willemsen RA; Debets R
    J Immunol Methods; 2010 Jul; 359(1-2):11-20. PubMed ID: 20460126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.